抗MAdCAM-1抗体(PF-00547659)治疗溃疡性结肠炎(TURANDOT):一项2期随机双盲安慰剂对照试验
TURANDOT是一项2期随机双盲安慰剂对照试验,纳入357例中重度活动性溃疡性结肠炎患者,比较PF-00547659四种剂量与安慰剂的诱导缓解效果。第12周时,7.5 mg、22.5 mg和75 mg组的缓解率显著高于安慰剂组,225 mg组未达显著;药物安全且耐受良好,22.5 mg和75 mg剂量临床效果最大。
要点
- 第12周缓解率:安慰剂组2.7%,7.5 mg组11.3%、22.5 mg组16.7%、75 mg组15.5%均显著优于安慰剂。
- 225 mg组缓解率5.7%,与安慰剂相比风险差2.6%(90%CI -1.2至6.4,p=0.1803),未达统计学显著。
- 22.5 mg和75 mg剂量观察到最大临床效应,未发现研究药物的安全性信号。
核心结论
- PF-00547659在该患者人群中安全且耐受良好,对中重度溃疡性结肠炎的诱导缓解优于安慰剂。
- 22.5 mg和75 mg剂量观察到最大的临床效应。
研究设计与样本
- 2期随机双盲安慰剂对照临床试验,从21个国家105个中心招募18-65岁患者。
- 纳入活动性溃疡性结肠炎病史≥3个月、病变超过肛缘15 cm以上(总Mayo评分≥6且Mayo内镜子评分≥2)且至少一种常规治疗失败或不耐受的患者。
- 按既往抗TNFα治疗分层,计算机生成随机序列分配至皮下注射PF-00547659 7.5 mg、22.5 mg、75 mg、225 mg或安慰剂,基线给药后每4周一次。
- 主要终点为第12周达到缓解(总Mayo评分≤2且无单项子评分>1且直肠出血子评分≤1)的患者比例。
- 疗效分析纳入所有接受至少一剂随机治疗的患者;安全性分析按实际接受治疗进行。
主要发现
- 2012年11月2日至2016年2月4日筛选587例,357例合格并随机分配至安慰剂(n=73)或PF-00547659 7.5 mg(n=71)、22.5 mg(n=72)、75 mg(n=71)、225 mg(n=70)。
- 第12周缓解率:安慰剂组2.7%(2/73),7.5 mg组11.3%(8/71),22.5 mg组16.7%(12/72),75 mg组15.5%(11/71),225 mg组5.7%(4/70)。
- 分层调整(抗TNFα初治和经治)后与安慰剂的风险差:7.5 mg组8.0%(90%CI 1.9至14,p=0.0425),22.5 mg组12.8%(5.6至19.9,p=0.0099),75 mg组11.8%(4.8至18.8,p=0.0119),225 mg组2.6%(-1.2至6.4,p=0.1803)。
- 严重不良事件:安慰剂组4/73(5.5%),7.5 mg组10/71(14.1%),22.5 mg组1/70(1.4%),75 mg组3/73(4.1%),225 mg组3/70(4.3%)。
- 未观察到研究药物的安全性信号。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PF-00547659 is a fully human monoclonal antibody that binds to human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to selectively reduce lymphocyte homing to the intestinal tract. We aimed to assess the efficacy and safety of PF-00547659 in patients with moderate to severe ulcerative colitis. METHODS: This phase 2, randomised, double-blind, placebo-controlled clinical trial recruited patients aged 18-65 years from 105 centres in 21 countries, with a history (≥3 months) of active ulcerative colitis extending more than 15 cm beyond the anal verge (with a total Mayo score ≥6 and a Mayo endoscopic subscore ≥2) who had failed or were intolerant to at least one conventional therapy. Patients were stratified by previous anti-TNFα treatment, and randomly assigned by a computer-generated randomisation schedule to receive a subcutaneous injection of 7·5 mg, 22·5 mg, 75 mg, or 225 mg PF-00547659 or placebo at baseline, then every 4 weeks. Patients, investigators, and sponsors were blinded to the treatment. The primary endpoint was the proportion of patients achieving remission (total Mayo score ≤2 with no individual subscore >1 and rectal bleeding subscore ≤1) at week 12. The efficacy analysis included all patients who received at least one dose of the randomised treatment; the safety analysis was done according to treatment received. All p values were one-sided and multiplicity-adjusted. This study is registered with ClinicalTrials.gov, number NCT01620255. FINDINGS: Between Nov 2, 2012, and Feb 4, 2016, we screened 587 patients; 357 were eligible and randomly assigned to receive placebo (n=73) or PF-00547659 at doses of 7·5 mg (n=71), 22·5 mg (n=72), 75 mg (n=71), or 225 mg (n=70). Remission rates at week 12 were significantly greater in three of four active-treatment groups than in the placebo group (2·7% [two of 73]): 7·5 mg (11·3% [eight of 71]), 22·5 mg (16·7% [12 of 72]), 75 mg (15·5% [11 of 71]), and 225 mg (5·7% [four of 70]). These rates corresponded to a stratum-adjusted (anti-TNFα-naive and anti-TNFα-experienced) risk difference versus placebo of 8·0% for 7·5 mg (90% CI 1·9 to 14, p=0·0425), 12·8% for 22·5 mg (5·6 to 19·9, p=0·0099), 11·8% for 75 mg (4·8 to 18·8, p=0·0119), and 2·6% for 225 mg (-1·2 to 6·4, p=0·1803). Four of 73 (5·5%) patients had a serious adverse event in the placebo group, ten of 71 (14·1%) in the 7·5 mg group, one of 70 (1·4%) in the 22·5 mg group, three of 73 (4·1%) in the 75 mg group, and three of 70 (4·3%) in the 225 mg group. No safety signal was observed for the study drug. INTERPRETATION: PF-00547659 was safe and well tolerated in this patient population, and better than placebo for induction of remission in patients with moderate to severe ulcerative colitis. The greatest clinical effects were observed with the 22·5 mg and 75 mg doses. FUNDING: Pfizer.
引用
- Vermeire S, Sandborn WJ, Danese S, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017. PMID: 28527704. doi:10.1016/S0140-6736(17)30930-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。